Pharmaceutical industry
Michael Porter, a renowned expert in competitive strategy and the Bishop William Lawrence University Professor at Harvard Business School, has joined the board of directors of Merrimack Pharmaceuticals, a privately held biotechnology company focused on cancer treatments. Porter's extensive research and experience in strategic development will significantly benefit
Pharmaceutical industry
Advanced follicular lymphoma patients who responded to initial treatment with Rituxan and chemotherapy now have a new maintenance option to prolong time without disease worsening. The FDA approval of Rituxan as a single-agent maintenance therapy for patients with advanced follicular lymphoma was based on data from the Phase III PRIMA
Pharmaceutical industry
U.S. markets experienced significant gains Monday, driven by favorable corporate reports and developments in the biotech industry. Alcoa and Intel led the charge, with share prices rising 4.05 percent and 2.02 percent, respectively. Meanwhile, General Electric shares surged 1.52 percent following its report of increased revenue
Pharmaceutical industry
DARA BioSciences, Inc. is a development-stage company based in Raleigh, NC, that acquires high-potential therapeutic molecules and medical technologies from pharmaceutical companies and academic institutions. The company focuses on taking these product candidates through clinical development and regulatory review submissions, after which they are licensed or acquired by pharmaceutical companies.
Pharmaceutical industry
The US stock market is showing a downward trend as of mid-day, with concerns over the European debt crisis dampening investor sentiment. Despite a lack of economic data releases, investors are closely watching deal news, with several companies reporting significant developments. The market's downward trend is also influenced
Pharmaceutical industry
The housing market has been a driving force in past recessions, but it has been derailed this time around due to the effects of the housing bubble. Despite this, the good news is that residential investment is unlikely to fall further, and its contribution to the overall economy is decreasing.
Pharmaceutical industry
In mid-day trading on December 13, 2010, health care stocks saw a significant surge as Sanofi-Aventis (SNY) extended its deadline for its hostile bid of Genzyme (GENZ). The Dow Jones U.S. Health Care Index rose 0.38, or 0.12%, to 325.25, with notable gains in individual stocks
Pharmaceutical industry
Teva Pharmaceutical Industries Ltd. and Active Biotech announced initial results from the two-year Phase III ALLEGRO study, demonstrating that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. The study also showed a significant
Pharmaceutical industry
Seattle Genetics and Millennium: The Takeda Oncology Company announced positive results from a phase II clinical trial of brentuximab vedotin (SGN-35) in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). The trial demonstrated an 86% objective response rate, with 53% of patients achieving a complete remission. Tumor reductions were
Pharmaceutical industry
The US Food and Drug Administration (FDA) Arthritis Advisory Committee has recommended approval for Benlysta (belimumab) to treat autoantibody-positive patients with active systemic lupus erythematosus. This development is a significant milestone for patients suffering from this debilitating autoimmune disease. The FDA has set a target date of December 9, 2010,
Pharmaceutical industry
The Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 2 to recommend the approval of BENLYSTA (belimumab) for the treatment of autoantibody-positive patients with active systemic lupus erythematosus (SLE). This decision comes after a thorough review of the clinical trial data submitted
Pharmaceutical industry
Insight Genetics has been selected by the National Cancer Institute (NCI) to develop a new test for lung cancer patients under a $200,000 Phase I Small Business Innovation Research (SBIR) contract. As part of the contract, Insight Genetics will further validate its Insight ALK Screen test, which detects cancer-causing
